NICE approves euthanrhus anti-inflammatory drug Cimzia (certolizumab pegol) for treatment of adult patients with plaque psoriasis

recently, the National Institute scare spree (NICE) approved the UCB anti-inflammatory drug Cimzia (certolizumab pegol) for the treatment of adult patients with severe plaque psoriasis who have no response to other systemic therapies or are not suitableAbout Cimzia
Cimzia is a biological agent that effectively prevents inflammation caused by overactivation of the immune systemPreviously, NICE has approved Cimzia for the treatment of moderate to severe active rheumatoid arthritis (RA) that has previously been treated with a TNF inhibitor, active psoriasis arthritis (PsA), severe active spinal arthritis (AS) that has been treated with a TNF inhibitor, and severe non-radiation spinal arthritis (n)Cimzia is the only anti-tumor necrosis factor alpha (TNF-alpha) withnosing fc domain, polyglycol-modified modification,drug(http://, has a very high affinity for human TNF-alpha, and is able to selectively and tNF-alpha."So far, Cimzia has been approved by many countries and regions around the world for the treatment of a variety of inflammatory diseases, including rheumatoid arthritis, psoriasis arthritis, stoic syllritis, spinal arthritis, Crohn's disease, etcAt the end of March, Cimzia was approved by the U.SFDA(http://for the treatment of adult patients with active non-radiative non-radiative axial spinal arthritis (nr-axSpA) with inflammatory signsthis approval, making Cimzia the first and only drug to receive FDA approval to treat nr-axSpA